SCHEMBL7522906

SCHEMBL7522906

Cc1c(N)c(C(N)=O)nn1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM3 Q86V86 2/20 0.41
DAPK3 O43293 1/20 0.41
PRKD3 O94806 1/20 0.41
MAP4K4 O95819 1/20 0.41
PRKACA P17612 1/20 0.41
LTK P29376 1/20 0.41
KDR P35968 1/20 0.41
MAP2K2 P36507 1/20 0.41
MAPK8 P45983 1/20 0.41
CSNK1A1 P48729 1/20 0.41
CDK8 P49336 1/20 0.41
CLK2 P49760 1/20 0.41
CDK9 P50750 1/20 0.41
CDK5 Q00535 1/20 0.41
MAP2K1 Q02750 1/20 0.41
PRKCQ Q04759 1/20 0.41
ACVR1 Q04771 1/20 0.41
ROCK1 Q13464 1/20 0.41
DYRK1A Q13627 1/20 0.41
CLK4 Q9HAZ1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL38664334 0.83 KDM4E (0.39) PIM3DAPK3PRKD3MAP4K4PRKACA
SCHEMBL16797981 0.83 GAA (0.39) PIM3DAPK3PRKD3MAP4K4PRKACA
SCHEMBL1225546 0.81 KDM4E (0.40) PIM3DAPK3PRKD3MAP4K4PRKACA
Hydrochloric Acid SCHEMBL28351488 0.79 KDM4E (0.39) PIM3DAPK3PRKD3MAP4K4PRKACA
SCHEMBL31581857 0.79 MAP4K1 (0.40) PIM3DAPK3PRKD3MAP4K4PRKACA
SCHEMBL7001118 0.78 ADORA2A (0.37) PIM3DAPK3PRKD3MAP4K4PRKACA
Bromide SCHEMBL7823529 0.76 ADORA2A (0.36) PIM3DAPK3PRKD3MAP4K4PRKACA
SCHEMBL6200869 0.75 ADORA2A (0.35) PIM3DAPK3PRKD3MAP4K4PRKACA
SCHEMBL6632048 0.75 ADORA2A (0.36) PIM3DAPK3PRKD3MAP4K4PRKACA
SCHEMBL6996899 0.72 NPSR1 (0.36) PIM3DAPK3PRKD3MAP4K4PRKACA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8703768-B2 Nitrogen containing heteroaryl compounds HOFFMANN-LA ROCHE INC. (US) 2014-04-22 US disclosed
US-8623866-B2 2014-01-07 US disclosed
EP-2580207-A1 NITROGEN CONTAINING HETEROARYL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2013-04-17 EP disclosed
WO-2011154327-A1 NITROGEN CONTAINING HETEROARYL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2011-12-15 WO disclosed
US-20110306589-A1 NITROGEN CONTAINING HETEROARYL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2011-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110306589-A1 NITROGEN CONTAINING HETEROARYL COMPOUNDS PDE10A, PDE3A, PDE2A PIM3 4303/4885DAPK3 3758/4885PRKD3 1910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.